ArticleFrontiers in pharmacology2024

Cost-effectiveness analysis of tislelizumab plus chemotherapy as the first-line treatment for advanced or metastatic esophageal squamous cell carcinoma in China.

Yanhong Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.